The Braf Inhibitor Vemurafenib Plus Rituximab Produces a High Rate of Deep and Durable Responses in Relapsed/Refractory Hairy Cell Leukemia: Updated Results of a Phase-2 Trial
Hematological Oncology - United Kingdom
doi 10.1002/hon.72_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley